Business Wire

HANSHOW

8.6.2021 04:02:06 CEST | Business Wire | Press release

Share
Hanshow Marks Retail Digitization at Breakthrough Scale on Microsoft Azure

Deploying scalable and affordable enterprise grade IoT applications in the retail industry has previously been restricted by technology limitations. But digital retail solutions leader Hanshow has now developed a SaaS solution that accelerates this digital transformation by connecting store shelves to retailers, store operators, and customers on an unprecedented scale by managing more than 10 million IoT devices across a vast network of Ahold Delhaize stores in Europe.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005244/en/

Ahold Delhaize and Hanshow began partnering in 2018 to install electronic shelf labels (ESL) and other digital solutions at select stores in Europe. This later expanded to cover hundreds of stores across Europe and over 10 million ESL – a tremendous number of devices to sync and manage.

ESLs are the building blocks of retail digitization, and effective solutions for connecting them are crucial to maximize efficiency and open up new digital solution possibilities. However, the ability to remotely manage tens of millions of ESL across hundreds of stores through one cloud-based network had not yet been possible until Hanshow partnered with Microsoft to develop a SaaS solution that can handle this massive amount of integration.

Adopting solutions through cloud services and IoT technology is rapidly growing in retail. Global research firm Gartner estimates, “Worldwide end-user spending on public cloud services is forecast to grow 18.4% in 2021 to total $304.9 billion, up from $257.5 billion in 2020”.* It further adds, “Although software as a service (SaaS) remains the largest market segment and is forecast to grow to $117.7 billion in 2021, application infrastructure services (PaaS) is anticipated to grow by a higher margin at 26.6%” *

The benefits of adopting such services are apparent through this partnership. The Hanshow SaaS solution addresses a number of challenges for retailers such as staffing surges during peak times, labor costs, space constraints, and overall productivity.

Under previous scenarios, retailers have to install and operate their own system of servers and infrastructure on premise requiring a massive investment, untold time to set up, and significant input from IT professionals.

The Hanshow SaaS Solution provides global retailers an intelligent, easy-to-deploy, user-friendly, and analytics driven platform. Hanshow SaaS is ready on arrival and can be accessed instantly anytime, anywhere. Data can be shared across geographies while remote monitoring and updates become a seamless exercise. Price updates and other ESL or digital solution updates can be done at breakneck pace; 3 million ESL can be updated in just 80 min. And with a focus on the heightened security needed from a cloud-based network, Hanshow carried out third-party security testing through a leading global security firm to certify data safety of the Microsoft Azure backed Hanshow SaaS.

“This scale and advancement in retail technology was made possible through the safety, stability, scalability and speed of Microsoft SaaS with Hanshow’s innovative management software,” said Raj Raguneethan, regional leader, Retail & Consumer Goods at Microsoft Asia. “With this work, we’re seeing only the beginning of what’s possible with IoT and SaaS.”

While over 10 million ESL have already integrated into the Hanshow SaaS, it can handle much more if necessary. “By integrating retail digitization with SaaS, the possibilities are endless,” said Hanshow Executive Chairman and CEO Shiguo Hou. “This is the future. We're committed to bringing these benefits to customers and retailers on an even grander scale.”

*Gartner Press Release, “Gartner Forecasts Worldwide Public Cloud End-User Spending to Grow 18% in 2021”, 17 November 2020, [https://www.gartner.com/en/newsroom/press-releases/2020-11-17-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-grow-18-percent-in-2021 ]

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. For more information, please visit www.hanshow.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye